Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that in men with benign prostatic hyperplasia, a 3-month treatment with a long-acting GnRH agonist significantly reduced intraprostatic DHT and 3α-diol levels by about 90% and testosterone by about 75%.

In this case report, treatment with antibiotics, finasteride, and prostate omentalization restored fertility in a 6-year-old German Shepherd with prostatitis and astenoteratozoospermia, avoiding surgical castration.

Combination therapy with Finasteride is more effective than alpha-blocker alone for BPH symptoms in small prostate volume.

This review discusses how the HSD3B1(1245C) genotype may impact androgen physiology and the progression of castration-resistant prostate cancer, and does not report new experimental results.

This study found that in rats, combined treatment with finasteride and doxazosin altered epithelial cell behavior and matrix metalloproteinases activity, suggesting effects possibly mediated by TGF-β1 and androgen pathways.

This study found that in patients undergoing allogeneic hematopoietic stem-cell transplantation, older age significantly increases the risk of hemorrhagic cystitis, especially in males, who are also affected by prostatic hyperplasia.

In this study, higher urethral prostate-specific antigen (urPSA) levels in men after radical prostatectomy were associated with higher androgenic alopecia scores and higher postoperative PSA.

This systematic review found that mixed epithelial and stromal tumor of the seminal vesicle (MESTSV) is characterized by abundant stromal proliferation, architectural heterogeneity, and strong immunoreactivity for ER/PR, with most being benign but warranting surveillance for possible recurrence or metastasis.

This study found that increased PSA levels in women with hyperandrogenism may serve as a diagnostic marker, comparable to free testosterone levels.

Hormonal interactions, especially involving DHT and estrogen, play a key role in BPH development and treatment.

This report describes a case of meningioma in a transwoman treated long-term with estradiol and cyproterone acetate, suggesting possible concern over female sex steroids and meningioma risk.

This review examines the role of steroidal inhibitors in treating prostatic diseases but presents no new clinical results.

Combining medications is more effective for treating benign prostatic syndrome symptoms.

This study identified 193 plasma proteins associated with prostate cancer risk, validating 20 high-risk proteins including KLK3, and pinpointed potential drug targets like HSPB1, RRM2B, and PSCA through genetic analysis, offering new insights for biomarkers and treatments.

This study found that both Finasteride and MK386 reduced cell proliferation in primary prostate cancer cultures, with Finasteride being more effective in lower Gleason scores and MK386 in higher ones.

Long-term use of finasteride may cause breast cancer in men.

This study found that PLX, a mixture of tomato extract and chitooligosaccharide, may reduce prostate weight in testosterone-induced BPH in rats, suggesting it could act as a 5α-reductase inhibitor.

This study found that transdermal DHT treatment increased penile length in boys with 5α-reductase type 2 deficiency, but post-pubertal growth was limited and carried potential prostate complications.

In this pilot randomized clinical trial, TRT combined with finasteride increased lean mass, muscle size, and bone mineral density without prostate enlargement in men with spinal cord injury, suggesting potential benefits for body composition and musculoskeletal health.

This review discusses the molecular mechanisms of masculinization involving androgen signaling and their roles in male embryonic development and conditions like hypospadias and prostate cancer, and reports no clinical results.

This study reported that Cosmos caudatus extract alone may therapeutically modulate the AR–FGF-2 axis in a BPH rat model, comparable to finasteride, but combining them disrupted pathway regulation, increasing TGF-β levels.

This study found that dutasteride significantly reduces the risk of acute urinary retention and surgical intervention in men with benign prostatic enlargement compared to placebo.

This editorial comment in the Journal of Urology discusses the implications of the Prostate Cancer Prevention Trial but reports no new research findings.

This study found that prostate cancer aggressiveness in men with obesity is associated with changes in age, BMI, testosterone, and estradiol levels, and that adipocyte-secreted molecules increase cancer cell aggressiveness in vitro.

This study found that after 12 months of treatment with 5 mg of finasteride, patients with benign prostatic hyperplasia showed reduced prostate volume, DHT and PSA levels, and improved urinary flow rates and symptoms.

In this study, Trapa bispinosa Roxb. pericarp extract demonstrated inhibitory effects on 5α-reductase activity both in vitro using LNCaP cells and in vivo in a mouse model of benign prostatic hyperplasia, suggesting its potential role in managing the condition.

In this study, preoperative use of finasteride was associated with reduced blood loss and vascular endothelial growth factor expression during TURP, suggesting a potential benefit in preventing transurethral resection syndrome.